K

Kansas City Research Institute | Kansas City, MO

Research site
(Unclaimed)
Location
6675 Holmes Road, Suite 430, Kansas City, Missouri, United States of America

Site insights

Top conditions

Top treatments

Obeticholic Acid
Filgotinib
Etrolizumab
DCV
Resmetirom
UDCA
eFT508
Emricasan
Daclatasvir
Ursodeoxycholic Acid

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 63 total trials
Locations recently updated

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Rese...

Enrolling
Nonalcoholic Fatty Liver Disease
Fatty Liver, Nonalcoholic
Drug: Semaglutide
Drug: Placebo

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling
Non-Alcoholic Fatty Liver Disease
Drug: Resmetirom

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling
NASH
Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: MGL-3196

This is a safety study to evaluate BOS-580 administered subcutaneously over 12 weeks in Part A or 24 weeks in Part B.

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Drug: BOS-580
Drug: Placebo

The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combina...

Enrolling
Carcinoma, Hepatocellular
Neoplasms
Drug: Lenvatinib
Drug: E7386
Locations recently updated

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes a...

Enrolling
Type 2 Diabetes
Drug: Semaglutide
Drug: Orforglipron

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling
Diabetic Gastroparesis
Drug: Placebo
Drug: CIN-102 Dose 2

This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).

Active, not recruiting
Crohn's Disease (CD)
Drug: ABT-494

To evaluate the long-term safety and tolerability of oral dersimelagon.

Active, not recruiting
EPP
XLP
Drug: MT-7117

The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy...

Active, not recruiting
Ulcerative Colitis
Drug: Filgotinib
Drug: Placebo

To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Inco...

Enrolling
Primary Biliary Cholangitis
Drug: Placebo
Drug: Seladelpar 10 mg

To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated...

Enrolling
X-Linked Protoporphyria (XLP)
Erythropoietic Protoporphyria (EPP)
Drug: Placebo
Drug: Dersimelagon
Locations recently updated

This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non al...

Active, not recruiting
Non-alcoholic Steatohepatitis
Drug: Placebo (NNC0194-0499)
Drug: NNC0174 0833 placebo
Locations recently updated

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Enrolling
Non-alcoholic Steatohepatitis
Drug: Placebo
Drug: Semaglutide

This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the effi...

Active, not recruiting
Cirrhosis
Prevention of Esophageal Varices
Drug: belapectin
Drug: Placebo

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: PTM CILO/FIR
Drug: Cilofexor (CILO)/Firsocostat (FIR)

Trial sponsors

Gilead Sciences logo
I
Madrigal Pharmaceuticals logo
Bristol-Myers Squibb (BMS) logo
C
G
Mitsubishi Tanabe Pharma logo
AbbVie logo
CymaBay Therapeutics logo
Effector Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems